May 6, 2025 01:30AM
Apr 24, 2024 01:00AM
Oct 23, 2023 01:00AM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Apr 27, 2023 01:00AM
Mar 2, 2023 02:13PM Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Feb 22, 2023 01:00AM
Feb 15, 2023 01:00AM
Feb 9, 2023 01:00AM
Jan 9, 2023 01:00AM
Oct 27, 2022 12:57AM
Aug 12, 2022 11:35AM
Aug 5, 2022 01:00AM Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
Jul 28, 2022 12:57AM
Jun 29, 2022 01:00AM
Jun 27, 2022 01:01AM
Jun 27, 2022 01:00AM
May 24, 2022 01:00AM
Feb 11, 2022 01:00AM
Jan 24, 2022 01:00AM Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
Aug 13, 2021 01:00AM
Jul 29, 2021 01:00AM
May 28, 2021 01:49PM
May 27, 2021 01:00AM
Apr 22, 2021 01:00AM
Apr 1, 2021 04:15PM
Mar 2, 2021 07:39AM Fusion Pharmaceuticals (FUSN) to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Mar 2, 2021 07:30AM
Feb 11, 2021 12:58AM
Sep 14, 2020 01:00AM
Sep 10, 2020 01:00AM
Aug 25, 2020 01:00AM
Jul 30, 2020 01:00AM
Jun 8, 2020 01:00AM Ipsen Demonstrates Continued Commitment to Rare Diseases With Eight Abstracts Accepted at ENDO 2020 Published in the Journal of the Endocrine Society
May 29, 2020 01:05AM
May 29, 2020 01:00AM
May 4, 2020 01:00AM
Mar 26, 2020 02:00AM
Feb 13, 2020 01:00AM
Jan 24, 2020 01:00AM
Oct 16, 2019 01:00AM Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Sep 26, 2019 01:00AM
Jul 25, 2019 01:00AM
May 28, 2019 01:30AM
May 24, 2019 01:00AM
May 14, 2019 01:00AM
Apr 24, 2019 01:00AM
Apr 18, 2019 01:00AM Ipsen Completes Acquisition of Clementia Pharmaceuticals
Feb 25, 2019 01:00AM

1,155,242 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All